MA34004B1 - Protéines de liaison à cd127 - Google Patents

Protéines de liaison à cd127

Info

Publication number
MA34004B1
MA34004B1 MA35147A MA35147A MA34004B1 MA 34004 B1 MA34004 B1 MA 34004B1 MA 35147 A MA35147 A MA 35147A MA 35147 A MA35147 A MA 35147A MA 34004 B1 MA34004 B1 MA 34004B1
Authority
MA
Morocco
Prior art keywords
antigen binding
binding proteins
protein link
diseases
protein
Prior art date
Application number
MA35147A
Other languages
Arabic (ar)
English (en)
Inventor
Ian Kirby
Alexander H Taylor
Thomas Matthew Webb
Yu Xue
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA34004B1 publication Critical patent/MA34004B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des protéines de liaison à un antigène qui se lient au récepteur humain de l'IL-7 (CD127). Les protéines de liaison à un antigène sont typiquement des anticorps, et sont utiles dans le traitement de maladies ou de troubles chez les êtres humains, particulièrement de maladies auto-immunes telles que la sclérose en plaques.
MA35147A 2010-01-28 2011-01-26 Protéines de liaison à cd127 MA34004B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29901010P 2010-01-28 2010-01-28
PCT/US2011/022507 WO2011094259A2 (fr) 2010-01-28 2011-01-26 Protéines de liaison à cd127

Publications (1)

Publication Number Publication Date
MA34004B1 true MA34004B1 (fr) 2013-02-01

Family

ID=44320081

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35147A MA34004B1 (fr) 2010-01-28 2011-01-26 Protéines de liaison à cd127

Country Status (26)

Country Link
US (2) US9150653B2 (fr)
EP (1) EP2528947A4 (fr)
JP (1) JP5850860B2 (fr)
KR (1) KR20130028055A (fr)
CN (1) CN102812046B (fr)
AR (1) AR080027A1 (fr)
AU (1) AU2011209713B2 (fr)
BR (1) BR112012018914A2 (fr)
CA (1) CA2787070A1 (fr)
CL (1) CL2012002081A1 (fr)
CO (1) CO6592067A2 (fr)
CR (1) CR20120404A (fr)
EA (1) EA023700B1 (fr)
IL (1) IL220899A (fr)
MA (1) MA34004B1 (fr)
MX (1) MX339083B (fr)
MY (1) MY160590A (fr)
NZ (1) NZ601271A (fr)
PE (2) PE20170687A1 (fr)
PH (1) PH12012501549A1 (fr)
SG (1) SG182590A1 (fr)
TW (1) TWI489996B (fr)
UA (1) UA104663C2 (fr)
UY (1) UY33202A (fr)
WO (1) WO2011094259A2 (fr)
ZA (1) ZA201205624B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3252076B1 (fr) 2011-01-14 2019-09-04 The Regents Of The University Of California Utilisation diagnostique d' anticorps thérapeutiques contre la protéine ror-1
EP2583980A1 (fr) * 2011-10-19 2013-04-24 Effimune Anticorps dirigés contre la chaîne alpha du récepteur IL7, leur utilisation pour la préparation de candidats médicaments
EP2955196A1 (fr) * 2014-06-10 2015-12-16 Effimune Anticorps dirigés contre CD127
US20170247460A1 (en) 2014-10-18 2017-08-31 Pfizer Inc. Anti-il-7r antibody compositions
AU2016239949A1 (en) 2015-03-31 2017-09-07 Sorriso Pharmaceuticals, Inc. Peptide construct having a protease-cleavable linker
WO2016156468A1 (fr) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
WO2017055966A1 (fr) 2015-10-01 2017-04-06 Pfizer Inc. Compositions d'anticorps à faible viscosité
WO2017120479A1 (fr) * 2016-01-07 2017-07-13 The Schepens Eye Research Institute, Inc. Thérapeutique pour maladies immuno-inflammatoires oculaires
MA43767B1 (fr) 2016-02-29 2019-08-30 Ose Immunotherapeutics Anticorps non antagonistes dirigés contre la chaine alpha du domaine extracellulaire du récepteur de l'il-7 et leur utilisation dans le traitement du cancer
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
CN110392695B (zh) 2016-12-09 2021-02-02 Ose免疫疗法 针对cd127的抗体和多肽
EP3735252A4 (fr) * 2018-01-04 2021-10-06 Avidity Biosciences, Inc. Molécules d'acide nucléique hétéroduplex et leurs utilisations
CN118894938A (zh) * 2019-01-22 2024-11-05 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
CA3144566A1 (fr) 2019-06-21 2020-12-24 Sorriso Pharmaceuticals, Inc. Polypeptides
US12570736B2 (en) 2019-06-21 2026-03-10 Sorriso Pharmaceuticals, Inc. Compositions
JP7692844B2 (ja) 2019-06-21 2025-06-16 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
CN110894237B (zh) * 2019-12-05 2021-08-03 山东省分析测试中心 抗cd127的抗体、分泌该抗体的细胞株及其制备方法和应用
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions
US20220389104A1 (en) * 2021-05-28 2022-12-08 Ose Immunotherapeutics Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent
JP2025518164A (ja) 2022-05-30 2025-06-12 オセ イムノセラピューティクス Ｉｌ７ｒモジュレーター活性のバイオマーカー
WO2024040195A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo
EP4646274A1 (fr) 2023-01-06 2025-11-12 Twain Therapeutics Pte. Ltd. Molécules de liaison à l'antigène
CN120858116A (zh) 2023-01-06 2025-10-28 泰温治疗私人有限公司 抗原结合分子
EP4455308A1 (fr) 2023-04-24 2024-10-30 Les Laboratoires Servier Signatures géniques il-7r
EP4719352A1 (fr) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Formulations et compositions de nanoparticules lipidiques
WO2025076113A1 (fr) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Lipides cationiques ionisables à espacement conservé et nanoparticules lipidiques
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025098341A1 (fr) * 2023-11-10 2025-05-15 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Anticorps ciblant il-7ra et leurs utilisations
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025202213A1 (fr) 2024-03-26 2025-10-02 Institut National de la Santé et de la Recherche Médicale Nanoparticule lipidique chargée d'agent antitumoral et fonctionnalisée pour cibler des cellules immosuppressives
WO2025217454A2 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables et nanoparticules lipidiques
WO2025217452A1 (fr) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Lipides cationiques ionisables contraints et nanoparticules lipidiques

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US20040049014A1 (en) * 1988-12-28 2004-03-11 Protein Design Labs, Inc. Humanized immunoglobulins
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
FI915911A7 (fi) 1989-06-15 1991-12-16 Immunex Corp Interleukiini-7-reseptoreja
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6800738B1 (en) * 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
CA2163032C (fr) 1993-06-03 2001-02-06 John Landon Fragments d'anticorps a des fins therapeutiques
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5795737A (en) 1994-09-19 1998-08-18 The General Hospital Corporation High level expression of proteins
JP2001523083A (ja) * 1994-12-23 2001-11-20 スミスクライン・ビーチャム・コーポレイション Ｉｌ−５により媒介される疾病の治療に有用な組み換えｉｌ−５アンタゴニスト
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
BR9708910A (pt) * 1996-05-04 1999-08-03 Zeneca Ltd Anticorpo conjugado sequência de polinucleotídeos vetor célula hospedeira hibridoma composição farmacêutica processos para fabricar um anticorpo ou um conjugado e para tratar um humano ou animal em necessidade deste tratamento
EE9900343A (et) 1997-02-07 2000-02-15 Merck & Co., Inc. Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
DE50015293D1 (de) * 1999-04-13 2008-09-11 Wilex Ag Diagnostischer und therapeutischer Einsatz von Antikörpern gegen den Urokinase-Rezeptor
CA2388245C (fr) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. L'utilisation de cellules de rat adaptess exemptes de serum pour produire de polypeptides heterologues
EP1332209B1 (fr) 2000-09-08 2009-11-11 Universität Zürich Groupes de proteines a domaines de repetition comprenant des modules de repetition
AU2002368077B2 (en) 2001-07-12 2010-03-04 Jefferson Foote Super humanized antibodies
EP1423510A4 (fr) 2001-08-03 2005-06-01 Glycart Biotechnology Ag Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
CA2832136C (fr) 2002-09-27 2015-11-17 Xencor Variants fc optimises et methodes destinees a leur generation
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20050025763A1 (en) * 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
CA2531238C (fr) 2003-07-04 2015-02-24 Affibody Ab Polypeptides presentant une affinite de liaison pour le recepteur 2 du facteur de croissance epidermique humain (her2)
WO2005019255A1 (fr) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteines de la lipocaline lacrymale
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
AU2005269759A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform
WO2006052660A2 (fr) * 2004-11-04 2006-05-18 Childrens Hospital Los Angeles Research Institute Blocage du recepteur il-7 pour supprimer l'immunite
EP2099827B1 (fr) 2006-12-18 2018-11-21 Genentech, Inc. Anticorps anti-notch3 antagonistes et utilisations de ces derniers dans la prophylaxie et le traitement de maladies liées à notch3
EP1958957A1 (fr) 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprenant un partie caractéristique des protéines appellées "Knottins"
US20090226442A1 (en) 2008-01-22 2009-09-10 Biogen Idec Ma Inc. RON antibodies and uses thereof
TW201018482A (en) 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment

Also Published As

Publication number Publication date
NZ601271A (en) 2014-09-26
WO2011094259A2 (fr) 2011-08-04
MX339083B (es) 2016-04-01
TW201136607A (en) 2011-11-01
CO6592067A2 (es) 2013-01-02
CR20120404A (es) 2012-10-04
AU2011209713B2 (en) 2014-04-03
US8940303B2 (en) 2015-01-27
CA2787070A1 (fr) 2011-08-04
BR112012018914A2 (pt) 2017-07-25
CN102812046B (zh) 2015-02-25
IL220899A (en) 2017-08-31
KR20130028055A (ko) 2013-03-18
US9150653B2 (en) 2015-10-06
AU2011209713A1 (en) 2012-09-13
WO2011094259A3 (fr) 2011-09-29
MX2012008765A (es) 2012-09-07
SG182590A1 (en) 2012-08-30
IL220899A0 (en) 2012-09-24
US20110200585A1 (en) 2011-08-18
UY33202A (es) 2011-08-31
PE20170687A1 (es) 2017-06-13
JP2013517799A (ja) 2013-05-20
ZA201205624B (en) 2014-01-29
CN102812046A (zh) 2012-12-05
UA104663C2 (xx) 2014-02-25
EA201290589A1 (ru) 2013-05-30
TWI489996B (zh) 2015-07-01
CL2012002081A1 (es) 2012-12-14
PH12012501549A1 (en) 2016-09-09
MY160590A (en) 2017-03-15
AR080027A1 (es) 2012-03-07
EP2528947A2 (fr) 2012-12-05
PE20121702A1 (es) 2012-12-14
EP2528947A4 (fr) 2013-09-18
JP5850860B2 (ja) 2016-02-03
US20120282254A1 (en) 2012-11-08
EA023700B1 (ru) 2016-07-29

Similar Documents

Publication Publication Date Title
EA201290589A1 (ru) Cd127-связывающие белки
PH12014502527B1 (en) St2 antigen binding proteins
PH12018501882A1 (en) Binding proteins and methods of use thereof
PH12013502205A1 (en) Antibodies to il-6 and their uses
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
EA201290570A1 (ru) Конструкты, связывающиеся с ron, и способы их использования
PH12014500167A1 (en) Tnf-alpha antigen-binding proteins with increased fcrn binding
EA201391457A1 (ru) Белки, связывающиеся с bcma (cd269/tnfrsf17)
WO2014114651A9 (fr) Protéines de liaison à l'antigène tnf-alpha
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
MX360403B (es) Proteinas de union a amiloide beta.
PH12013500933A1 (en) Methods and compositions for neural disease immunotherapy
MY199321A (en) Oncostatin m receptor antigen binding proteins
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
MX360163B (es) Moleculas de union il-6.
EA201590918A1 (ru) Антитела к bmp-6
CY1123519T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß
WO2011116212A3 (fr) Agents de liaison de récepteur de protéine morphogénétique osseuse et procédés de leur utilisation
MY149448A (en) Interleukin-21 receptor binding proteins